Category: St. Jude Medical
The Centers for Medicare & Medicaid Services release a proposal for reimbursement of transcatheter aortic valve implantation procedures, a boon for Edwards Lifesciences' Sapien and its position as the only replacement valve system with FDA clearance for the U.S. market.
Updated 12:10 p.m. with comments from Edwards Lifesciences.
Clockwise from top left: Medtronic's CoreValve, Edwards Lifesciences' Sapien, St. Jude Medical's Portico
The Centers for Medicare & Medicaid Services released a proposal detailing guidelines for reimbursement of transcatheter aortic valve implantation procedures for treating severe symptomatic aortic stenosis.
Boston Scientific plans to use the bulk of the $1 billion of the free cash flow it expects to generate this year on acquisitions, according to CFO Jeff Capello; also, Intuitive Surgical, Zoll hit 52-week highs; and analysts' ups and downs.
Boston Scientific (NYSE:BSX) plans to hoard most of the more than $1 billion in free cash flow it expects to generate this year so it can make acquisitions to boost its top line, CFO Jeff Capello told analysts last week.
AngioDynamics CEO Joseph DeVivo tells MassDevice that the $372 million deal to acquire Navilyst Medical is a chance to set the combined companies on a sound foundation; plus, CEO pay: $1.4M for no growth?; Greenway Medical readies IPO; Exactech releases Q4 prelims, 2012 guidance; and analysts' ups and downs.
Updated February 1, 2012 at 5:30 p.m.
The $372 million buyout of Navilyst Medical by AngioDynamics (NSDQ:ANGO) is a reset button that will reinforce the combined operation for the future, AngioDynamics CEO Joe DeVivo told MassDevice this afternoon.
Zoll Medical Corp.
, Exactech Inc.
, Align Technology Inc.
, Becton Dickinson & Co.
, Boston Scientific
, C.R. Bard
, Cynosure Inc.
, Danaher Corp.
, Edwards Lifesciences
, Greenway Medical Technologies Inc.
, Intuitive Surgical Inc.
, Navilyst Medical Inc.
, Smith & Nephew
, St. Jude Medical
, Thoratec Corp.
, Abiomed Inc.
, Angeion Corp.
, AngioDynamics Inc.
J&J's DePuy to stop selling all custom devices; FDA announces 2012 medical device priorities; cardiologists charged with Medicare fraud in over-stenting cases; Sanovas expands ahead of commercial launch; St. Jude responds to Riata summit; and a judge rules Cordis patents invalid.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
The outlook for venture capital this year has its bright and dark spots, according to National Venture Capital Assn. president Mark Heesen; also, PE climate "schizo"; Leerink Swann sees upside in health care market; a bullish take on St. Jude Medical; and analysts' ups and downs.
The volatility of the stock markets last year was mirrored in the venture capital arena, according to Mark Heesen, president of the National Venture Capital Assn.
"Be prepared for a roller coaster ride here, because that’s where we’ve been for the past year – and that’s where we’re going," Heesen told Xconomy.
, Baxter International
, Edwards Lifesciences
, HeartWare International Inc.
, Hill-Rom Holdings Inc.
, Leerink Swann
, National Venture Capital Assn.
, ResMed Inc.
, St. Jude Medical
, 3M Corp.
Thoratec Corp. says it's settled a beef with activist investor group Oracle Investment Management over whether to sell the company; also, NuVasive jumps on legal ruling; Oridion releases Q4, 2011 prelims; AngioDynamics announces recall, updates guidance; cosmetic device market on the mend?; and analysts' ups and downs.
Thoratec Corp. (NSDQ:THOR) said it reached an agreement with one of its major institutional shareholders, Oracle Investment Management, over whether or not the heart pump maker should hire an investment bank to find a buyer.
Greenwich, Conn.-based Oracle, which holds a 5.2% stake in the heart pump maker, recommended that Thoratec retain an investment bank to explore strategic alternatives, including sale to a larger company.
St. Jude gained a few points on Wall Street by beating analysts' profit expectations for 2011 by a penny.
St. Jude Medical (NYSE:STJ) got a little love from Wall Street after posting 2011 earnings results that beat analysts' forecasts by 1 cent.
The St. Paul, Minn.-based medical device maker posted $5.61 billion in sales for 2011, an 8.7% bump over $5.17 billion in 2010.
Non-adjusted earnings slid to $864 million, or $2.64 earned per diluted share, representing a 4.7% decrease from the $907 million, or $2.75 per diluted share, earned in 2010.